E

A dozen early stage clinical trials to watch out for at AACR24

In 2011 we did an annual ASCO highlight video reel of what to watch out for. Three phase 1…

March 14, 2024
E

SITC23 Scorecard for emerging novel IO therapies

W2W4 at SITC23 - 10 emerging areas to pay attention to in IO

November 6, 2023
E

ESMO23 Preview 1 – Hype over Hope?

Parsing cancer research hype at ESMO23

September 27, 2023
E

Changing of the guard

How the landscape in prostate cancer could change in the medium to long term

February 17, 2023
E

Kaizen in action

The evolving BMS-Celgene pipeline and what's coming next in new developmental twists

January 10, 2023
E

ESMO22 Developmental Therapeutics Preview on Immunotherapies

In our latest ESMO conference preview it’s time to pick some early stage immunotherapy highlights…

August 31, 2022
E

Take the high road

5 abstracts to watch out for at the ASCO22 meeting in Chicago

May 2, 2022
E

What to watch at AACR22 on NK cells

What to watch out for at AACR22 if you're interested in NK cells

March 29, 2022
E

What’s the next stop in CAR T cell therapy?

Highlights from Day 1 of CART22, part 1

February 11, 2022
E

Tackling a hostile tumour microenvironment on multiple fronts

Continuing our ongoing series on immunosuppression and finding ways to overcome the hostile TME

June 24, 2021
E

5 early developments to watch out for at AACR21

What's hot in early preclinical development to watch out for?

April 5, 2021
E

What’s the skinny on a new IO target in oncology R&D?

A new emerging IO target of interest caught out attention, now what?

July 28, 2020
E

Are gamma delta T cells ready yet for prime time?

Update on the Gamma Delta T cell niche - what's new, what's up, and what's down?

July 1, 2020
E

The Potential of CAR-NK Cells for Cancer Immunotherapy

Will CAR-NK cells follow CAR-T cell therapies and hit prime time?

May 13, 2020
E

JPM20 Highlights from Day 2

Highlights (and lowlights) from the second day of the JPM Healthcare conference in San Francisco

January 14, 2020
E

Are 𝞬𝝳 T cells immuno-suppressive and should we delete them?

As look at ways of targeting 𝞬𝝳 T cells, we may need to consider whether or not the situation is immunosuppressive or proliferative

April 17, 2019
E

Gamma delta T cell cancer immunotherapy in China

What can we learn about gamma delta T cell cancer immunotherapy in China?

February 28, 2019
E
Aerial View Thames Estuary

Emerging Gamma Delta T Cell Cancer Immunotherapy Landscape

A look at the γδ T cell competitive landscape with cell therapies, antibodies and bispecifics in early stage development

February 27, 2019
E

Are gamma delta T cells the next wave of cell therapies?

Can we make novel allogeneic cell therapies with γδ T cells? We find out!

February 26, 2019
E

A Voyage of Discovery

Can γδ T cells be employed as a therapeutic against cancer?

February 25, 2019
E
TC BioPharm Office Building

TC BioPharm leads the way in allogeneic gamma delta T cells

TC BioPharm are a cell therapy company to watch out for as they look towards an IPO in 2020

March 4, 2019